Summary current Position, page-2

There is something here bigger behind just a few trolls XC , the EU sites being told that the FDA will not allow SSH to re-commence after the 4 deaths by the competition is disgraceful and desperate behavior just to pick extra patients? its more than that confirming my thoughts I've had for some time , the competition appears to be trying to defeat SSH and C-Pulse every way possible including trashing the share price starving SSH of funds , even with paid trolls to discredit SSH? they can delay but not defeat , the more patients that are implanted the more evidence C-Pulse gives relief and stops the CHF progression in patients will be evident , with many $ billions involved one can't underestimate the length a competitor will go , market share will be effected down stream for the competition when SSH receives FDA approval .

What we want for Xmas

SSH gets NUB1 through the new consultant early.
50 enrollments
successful chronic animal trial with fully implantable

Share price should be $2o if all that happens.